Abstract:Alzheimer's Disease (AD) is a devastating neurodegenerative disorder without cure. Lack of the understanding of early molecular mechanisms hinders the development of efficient therapeutics. We have previously demonstrated that alterations in mitochondrial dynamics precede the onset of memory phenotype and the development of amyloid plaques in three transgenic animal models of familial Alzheimer's Disease (FAD). Here we provide evidence that treatment with CP2, a member of a family of tricyclic pyrone compounds, restores axonal trafficking in vivo, and averts cognitive and motor deficit in FAD (APP, PS1 and APP/PS1) mice. Changes in mitochondrial dynamics and function in vivo and in vitro were evaluated using real-time imaging of mitochondrial motility; mitochondrial respiration and the rate of glycolysis were detected using a XF24 Seahorse Extracellular Flux Analyzer; evaluation of the activity of OXFOS Complexes I-V was done using enzymatic reactions; and metabolic changes associated with CP2 treatment were done using LC- and GC-MS-based metabolomics. Behavior and memory functions in treated and untreated animals were detected with a battery of well established tests including novel object recognition test, rotarod, hanging bar, Y-maze test, and activity in a cage. CP2 did not cause adverse side effects and did not affect animal breeding. CP2-treated animals maintained normal weight; they also outperform untreated FAD mice and age-and gender-matched non-transgenic littermates in a battery of tests. Cognitive protection was achieved within 2 months after treatment of presymptomatic animals. Investigation of the molecular mechanism revealed that CP2 treatment restores mitochondrial dynamics in neurons in vivo and in vitro. Alleviation of the motor and memory phenotype was accompanied by only partial reduction in amyloid burden. Moreover, we detected an increase in synaptophysin levels in the brain of CP2-treated APP/PS1 mice compared to untreated animals, which correlated with an improvement in cognitive function. Our findings, for the first time, demonstrated that restoration of mitochondrial trafficking protects against cognitive dysfunction in AD. Our data poise CP2 as a promising therapeutic compound validating mitochondrial motility as an early therapeutic target for AD.

CMS121, a Novel Drug Candidate for the Treatment of Alzheimer's Disease and Age-Related Dementia

NMN Synbiotics: A Multifaceted Therapeutic Approach for Alzheimer’s Disease

Design, Synthesis, and Biological Evaluation of Ferulic Acid Template-Based Novel Multifunctional Ligands Targeting NLRP3 Inflammasome for the Management of Alzheimer's Disease

Tetradecyl 2,3-Dihydroxybenzoate Improves Cognitive Function in AD Mice by Modulating Autophagy and Inflammation Through IPA and Hsc70 Targeting

Design, Synthesis, and Pharmacological Characterization of Sulfonylurea-Based NLRP3 Inhibitors: Towards an Effective Therapeutic Strategy for Alzheimer's Disease

Design, Synthesis, and Biological Evaluation of Ferulic Acid-Piperazine Derivatives Targeting Pathological Hallmarks of Alzheimer's Disease

Combined targeting of pathways regulating synaptic formation and autophagy attenuates Alzheimer's disease pathology in mice

New Multi-Target-directed Small Molecules Against Alzheimer's Disease: a Combination of Resveratrol and Clioquinol.

JNK inhibitor and ferroptosis modulator as possible therapeutic modalities in Alzheimer disease (AD)

Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease <i>in vitro</i> and <i>in vivo</i>

RESTORATION OF AXONAL TRAFFICKING OF MITOCHONDRIA AVERTS COGNITIVE DECLINE IN MOUSE MODELS OF FAMILIAL ALZHEIMER'S DISEASE

A Phase Ib Multiple Ascending Dose Study of the Safety, Tolerability, and Central Nervous System Availability of AZD0530 (saracatinib) in Alzheimer's Disease.

Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease in vitro and in vivo

Clinical Update on an Anti-Alzheimer Drug Candidate CT1812: A Sigma-2 Receptor Antagonist

Design, Synthesis and Evaluation of Novel Dual Monoamine-Cholinesterase Inhibitors As Potential Treatment for Alzheimer’s Disease

Design, Synthesis, and Evaluation of Novel O-alkyl Ferulamide Derivatives As Multifunctional Ligands for Treating Alzheimer’s Disease

Novel Cinnamamide-Dibenzylamine Hybrids: Potent Neurogenic Agents with Antioxidant, Cholinergic, and Neuroprotective Properties As Innovative Drugs for Alzheimer's Disease

Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease

Agents at the Peak of US FDA Approval for the Treatment of Alzheimer's Disease

Sildenafil as a Candidate Drug for Alzheimer's Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons

A Novel Small Molecule Modulator of Amyloid Pathology